8993-D7
MDCi010-A
General
Cell Line |
|
hPSCreg name | MDCi010-A |
Cite as: | MDCi010-A (RRID:CVCL_C0HG) |
Alternative name(s) |
8993-D7
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
UNIZARi001-A (FiPSTK2-2) Donor's gene variants: TK2, TK2 Donor diseases: Mitochondrial DNA depletion syndrome, myopathic form |
Last update | 23rd August 2022 |
User feedback | |
Provider |
|
Generator | Max Delbrück Center Berlin Buch (MDC) |
Distributors | |
Derivation country | Germany |
External Databases |
|
BioSamples | SAMEA12276594 |
Cellosaurus | CVCL_C0HG |
Wikidata | Q112930104 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Unknown
|
External Databases (Donor) |
|
BioSamples | SAMEA12276593 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Ethikausschuss am Campus Virchow-Klinikum |
Approval number | EA2/131/13 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type | |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method | Enzymatically |
O2 Concentration | 5 % |
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium: StemMACS iPS-Brew XF
Main protein source: Serum concentration: % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
NANOG |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
SMA |
Yes |
FN1 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
PAX6 |
Yes |
beta-tubulin III (TUJ1) |
Yes |
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
figure of virtual karyotype
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.